Company Profile

Public information reviewed
Adagene Inc. logo

Adagene Inc.

Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer.

USNASDAQ: ADAG
Public sources
1 reviewed
Published leadership records
17
Last reviewed
Sep 12, 2026
View sources

Company overview

Business, legal identity, ownership structure and classifications.

What the company does

About

Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for indi

Sector and industry values retain their source labels. A classification provider, taxonomy version and assignment date are not established unless the cited record states them.

Stable business record

Identity and status

Ownership and listing state

Public listing published

Ownership not asserted

The canonical public record includes at least one active security listing.

Inspect status source
Legal name
Adagene Inc.
Inspect source
Sector
Healthcare
Inspect source
Industry
Biotechnology
Inspect source

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 13, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Governance

Board leadership, management, committees and their disclosed responsibilities.

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

11 public records
PL
Peter Luo, Ph.D

Co-Founder, Chief Executive Officer, President of R&D, and Chairman of the Board

Board chairIndependence not stated
State
confirmed
Effective
Date not stated
Confidence
95%

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 12, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.

Board roles

6 public records

Disclosure boundary

Governance and independence

Only current, confirmed leadership roles with public evidence are included in the canonical projection.

RecordStatusAuthorityEffective

Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.

Investors & capital

Ownership, funding and dated financial information.

Ownership disclosures retain their reporting dates and source types. Economic ownership, investment discretion and voting authority are distinct. Activism and settlement-dated short interest are not established by holdings or short-sale volume.

Risk & assurance

Disclosed coverage, ratings and assurance scope.

Credit-rating evidence, where published, appears in the Governance and Basis sections with its source and reporting date. Insurance coverage, cyber ratings and assurance reports require their own issuer, scope, date and usage rights. Indemnification does not establish insurance coverage.

Ecosystem

Published relationships and related records.

Connections

Explore the roles, education and affiliations published in this record.

Alexander Goergen

Open Alexander Goergen profile →

Alexander Goergen: Vice President, Head of Business Development

Start not stated → End not stated

Date not established · source reported

Observed: 2026-09-12

Alexander GoergenAlexander GoergenAndy (Yiu Leung) C…Andy (Yiu Leung) CheungCuong DoCuong DoGuizhong Liu, Ph.D.Guizhong Liu, Ph.D.Jiping ZhaJiping ZhaLi Zhu, Ph.D.Li Zhu, Ph.D.Man Kin (Raymond) …Man Kin (Raymond) Tam, M.B.A., B. Eng.Mickael Chane-DuMickael Chane-DuPeter Luo, Ph.DPeter Luo, Ph.DQinghai Zhao, Ph.DQinghai Zhao, Ph.DSongmao Zheng, Ph.D.Songmao Zheng, Ph.D.Ulf Grawunder, Ph.D.Ulf Grawunder, Ph.D.Adagene Inc.

Dashed lines mark past roles. Select a connection to see its dates and sources.

Basis

Identifiers, sources and record limitations.

Identifiers

Alpha ID
alpha:company:b925afbb-e483-491c-b195-7a680f06601e
Record version
public-1

Sources

Sources and published information

Alpha canonical company public projection

Supports Company identity, Published leadership, Entity status boundary.

Open source
State
Published
Source type
canonical_identity
Last reviewed
Sep 12, 2026